Cardiol Therapeutics
CRDL
38 hedge funds and large institutions have $7.44M invested in Cardiol Therapeutics in 2025 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 14 increasing their positions, 9 reducing their positions, and 9 closing their positions.
7,650% more call options, than puts
Call options by funds: $155K | Put options by funds: $2K
56% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 9
0.28% more ownership
Funds ownership: 9.18% → 9.46% (+0.28%)
12% less funds holding
Funds holding: 43 → 38 (-5)
23% less capital invested
Capital invested by funds: $9.6M → $7.44M (-$2.16M)
56% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$323K |
| 2 |
AI
AdvisorShares Investments
Bethesda,
Maryland
|
+$123K |
| 3 |
TC
Tejara Capital
London,
United Kingdom
|
+$97.7K |
| 4 |
UBS AM
Chicago,
Illinois
|
+$67.5K |
| 5 |
LSA
Lion Street Advisors
Austin,
Texas
|
+$32K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$178K |
| 2 |
PAM
PVG Asset Management
Golden,
Colorado
|
-$61.3K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$46.8K |
| 4 |
VF
Virtu Financial
New York
|
-$39.3K |
| 5 |
LPL Financial
San Diego,
California
|
-$23.4K |
CRDL Hedge Fund Activity: Q1 2025 in Review
38 of the 7,472 institutional investors tracked by Wall St. Rank reported a position in Cardiol Therapeutics (CRDL) for Q1 2025, worth a combined $7.44M — down 23% from $9.6M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of CRDL and 4 opened new positions — a net loss of 5 holders — while 9 trimmed existing stakes and 14 added.
The largest buyer was UBS Group, adding an estimated $323K. The largest seller was Morgan Stanley, cutting an estimated $178K.
- 38 institutional investors held Cardiol Therapeutics (CRDL) as of Q1 2025, down from 43 in Q4 2024.
- Funds reported $7.44M of Cardiol Therapeutics stock for Q1 2025, down 23% quarter-over-quarter.
- 4 funds opened new Cardiol Therapeutics positions in Q1 2025 and 9 closed out, a net change of -5 holders.
- The largest Cardiol Therapeutics buyer in Q1 2025 was UBS Group, an estimated $323K added.
- The largest Cardiol Therapeutics seller in Q1 2025 was Morgan Stanley, an estimated $178K sold.
Based on aggregated 13F filings for Q1 2025.